Top Tweets for #KEYNOTE426
Watch an analysis of top abstracts from #ASCO24 in #GU #Cancer with experts Dr. Christian Kollmannsberger, @LuciaNappi4 and @navstruck.
https://t.co/JszHahIlp8
#CHAARTED2 #TheMAST #EMBARK #CYCLONE2 #PSMAfore #CLEAR #KEYNOTE426 #IMmotion010 #GUCancer #MedOnc
From trial to treatment: exploring the lasting impact of #KEYNOTE426 in #KidneyCancer. @brian_rini @VUMC_Cancer and @PBarataMD @caseccc discuss five-year follow-up data and emphasize the importance of giving pts access to all active mechanisms upfront > https://t.co/uWiFiUZcVT
From trial to treatment: exploring the lasting impact of #KEYNOTE426 in #KidneyCancer. @brian_rini @VUMC_Cancer and @PBarataMD @caseccc discuss five-year follow-up data and emphasize the importance of giving pts access to all active mechanisms upfront > https://t.co/uWiFiUZcVT
From trial to treatment: exploring the lasting impact of #KEYNOTE426 in #KidneyCancer. @brian_rini @VUMC_Cancer and @PBarataMD @caseccc discuss five-year follow-up data and emphasize the importance of giving pts access to all active mechanisms upfront > https://t.co/uWiFiUZcVT
From trial to treatment: exploring the lasting impact of #KEYNOTE426 in #KidneyCancer. @brian_rini @VUMC_Cancer and @PBarataMD @caseccc discuss five-year follow-up data and emphasize the importance of giving pts access to all active mechanisms upfront > https://t.co/uWiFiUZcVT
#ASCO23 | Giuseppe Procopio ha commentato per noi i dati a conferma dei benefici in PFS e OS di #pembrolizumab + #axitinib nel trattamento del #RCC metastatico.
https://t.co/fGneVH0Qrl
#KEYNOTE426 @gippo27 @IstTumori
Pembrolizumab + axitinib vs sunitinib as first-line therapy for advanced clear cell #RCC: 5-year analysis of #KEYNOTE426. Presentation by @brian_rini @VUMC_Cancer. #ASCO23 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/SIm0ApOcCT @ASCO
Terrific discussion by @BraunMDPhD on role and timing IO/IO vs IO/TKI combinations in first and second line management of #RCC. Synthesizing landmark trials presented by @brian_rini @DrChoueiri Thomas Huston @TexasOncology #Keynote426 #CONTACT #CLEAR #ASCO23
@BraunMDPhD discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO @ASCO #ASCO23
![apolo_andrea's tweet photo. @BraunMDPhD discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO @ASCO #ASCO23 https://t.co/SF9e7ilNth](https://pbs.twimg.com/media/Fx4B5NwWwAcv1sh.jpg)
![apolo_andrea's tweet photo. @BraunMDPhD discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO @ASCO #ASCO23 https://t.co/SF9e7ilNth](https://pbs.twimg.com/media/Fx4B5NuWYAEtwT-.jpg)
![apolo_andrea's tweet photo. @BraunMDPhD discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO @ASCO #ASCO23 https://t.co/SF9e7ilNth](https://pbs.twimg.com/media/Fx4B5NtXoAQtM94.jpg)
![apolo_andrea's tweet photo. @BraunMDPhD discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO @ASCO #ASCO23 https://t.co/SF9e7ilNth](https://pbs.twimg.com/media/Fx4B5NtXgAEAy_A.jpg)
Awesome and timely summary by @brian_rini based on the data we just heard on #KEYNOTE426 and #CLEAR.
@ASCO #ASCO23
Great data throughout. Longest f/u with Nivo/Ipi and pembro/axi.
Cross-trial comparisons are always tough but the pembro/len data looking increasingly good with a high CR rate and very few primary PD.
Main question now is how long will these CRs last. Looking good so far but we will need to see how these look at 5-10 years f/u and beyond!
@urotoday @BraunMDPhD @OncBrothers @DrChoueiri @brian_rini @NazliDizman @montypal @Chrislabaki1 @ReneeSaliby @NazliDizman @ZeynepZengin @lalaniMD @xiaoweimd @VincentWenxinXu @DrDanielHeng @TiansterZhang @DrYukselUrun @OncoAlert
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
Always articulate @brian_rini brings through long term follow up of #Keynote426 axi-pembro — w/ excellent OS and prolonged PFS — 30% without progression at 5 yrs.
Great to see for patients w #kidneycancer. @asco #ASCO23 @OncoAlert
Now @brian_rini presenting an update on #KEYNOTE426 with the longest follow-up to date of an IO-TKI trial in clear cell RCC.
@ASCO #ASCO23
Continues to be associated with great outcomes. As we continue to accumulate longer follow-up that looks good with IO-TKI, what is the role of Nivo/Ipi vs the IO-TKI combos? Perhaps selection based on IMDC poor risk and S/R RCC which seem to benefit most from Nivo/Ipi.
@DrChoueiri @BraunMDPhD @OncBrothers @IMG_Oncologists @Chrislabaki1 @DrTHut @HemOncToday @HemOncFellows @Hemoncq @urotoday @VJOncology @OncoAlert
#KidneyBladder oral session continues with @brian_rini presenting #KEYNOTE426 phase 3 long term 5 year follow up showing persistent benefit of #axitinib + #pembro vs #sunitinib in metastatic#RCC @ASCO #ASCO23
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
12/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
#KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
🔹Diarrhea
🔸HTN
🔹Hypothyroidism
🔸Fatigue
🔹PPES
🔸Loss of appetite
12/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
#KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
🔹Diarrhea
🔸HTN
🔹Hypothyroidism
🔸Fatigue
🔹PPES
🔸Loss of appetite
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.7M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.8M followers
Kim Kardashian
@kimkardashian
70.1M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers